Ptc Therapeutics (PTCT) Revenue (2012 - 2026)

Ptc Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $360.5 million for Q2 2026.

• In Q2 2026, Revenue rose 101.55% year-over-year to $360.5 million; the TTM figure through Jun 2026 stood at $1.0 billion (down 42.84% YoY), while the FY2025 annual figure was $1.7 billion, up 114.51% from the prior year.
• Revenue for Q2 2026 stood at $360.5 million, up from $272.6 million in the prior quarter.
• The five-year high for Revenue was $1.2 billion in Q1 2025, with the low at $148.7 million in Q1 2022.
• The 5-year median for Revenue is $211.0 million (2025), against an average of $271.8 million.
• The sharpest annual moves came in 2025 and 2026: Revenue surged 459.73% in 2025, then tumbled 76.83% in 2026.
• Ptc Therapeutics' Revenue stood at $167.4 million in 2022, then surged by 83.41% to $307.1 million in 2023, then slumped by 30.58% to $213.2 million in 2024, then retreated by 22.75% to $164.7 million in 2025, then jumped by 118.92% to $360.5 million in 2026.
• Business Quant data shows PTCT's Revenue at $360.5 million in Q2 2026, $272.6 million in Q1 2026, and $164.7 million in Q4 2025.